GlobeNewswire: Salarius Pharmaceuticals Contains the last 10 of 24 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:06:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/03/04/1995041/0/en/Salarius-Announces-Allowance-of-New-European-Patent-Covering-Seclidemstat.html?f=22&fvtc=4&fvtv=55797Salarius Announces Allowance of New European Patent Covering Seclidemstat2020-03-04T13:00:00Z<![CDATA[European Patent Office Satisfied Patent Application Meets All Requirements]]>https://www.globenewswire.com/news-release/2020/03/02/1993416/0/en/Salarius-Pharmaceuticals-to-Attend-the-Oppenheimer-Healthcare-Conference.html?f=22&fvtc=4&fvtv=55797Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference2020-03-02T13:00:00Z<![CDATA[HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief executive officer, David Arthur, will be attending the 30th Annual Oppenheimer Healthcare Conference being held in New York City.]]>https://www.globenewswire.com/news-release/2020/02/11/1983392/0/en/Salarius-Announces-Closing-of-11-0-Million-Underwritten-Public-Offering-and-Full-Exercise-of-Over-Allotment-Option.html?f=22&fvtc=4&fvtv=55797Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option2020-02-11T21:05:00Z<![CDATA[HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the closing of its previously announced underwritten public offering, with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius.]]>https://www.globenewswire.com/news-release/2020/02/10/1982288/0/en/Salarius-Pharmaceuticals-to-Present-at-the-Noble-Capital-Markets-16th-Annual-Small-Microcap-Investor-Conference.html?f=22&fvtc=4&fvtv=55797Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference2020-02-10T13:00:00Z<![CDATA[HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference (NobleCon 16) being held February 16-18, 2020 in Hollywood, FL.]]>https://www.globenewswire.com/news-release/2020/02/07/1981771/0/en/Salarius-Announces-Pricing-of-9-6-Million-Underwritten-Public-Offering.html?f=22&fvtc=4&fvtv=55797Salarius Announces Pricing of $9.6 Million Underwritten Public Offering2020-02-07T13:30:57Z<![CDATA[HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius.]]>https://www.globenewswire.com/news-release/2020/02/05/1980201/0/en/Salarius-Pharmaceuticals-to-Present-at-the-BIO-CEO-Investor-Conference.html?f=22&fvtc=4&fvtv=55797Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference2020-02-05T13:00:00Z<![CDATA[HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the BIO CEO & Investor Conference being held February 10-11, 2020 in New York City.]]>https://www.globenewswire.com/news-release/2020/02/04/1979434/0/en/Salarius-Announces-Publication-of-Scientific-Paper-Highlighting-Potential-of-Combining-Seclidemstat-with-Checkpoint-Inhibitors.html?f=22&fvtc=4&fvtv=55797Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors2020-02-04T13:00:00Z<![CDATA[Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study]]>https://www.globenewswire.com/news-release/2019/12/19/1962760/0/en/Salarius-Pharmaceuticals-to-Present-at-Biotech-Showcase-2020.html?f=22&fvtc=4&fvtv=55797Salarius Pharmaceuticals to Present at Biotech Showcase 20202019-12-19T13:00:00Z<![CDATA[HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, announced today that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.]]>https://www.globenewswire.com/news-release/2019/12/17/1961523/0/en/Salarius-Pharmaceuticals-Hosting-Key-Opinion-Leader-Call-on-Epigenetics-The-Regulatory-System-That-Affects-Gene-Expression.html?f=22&fvtc=4&fvtv=55797Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression2019-12-17T13:00:00Z<![CDATA[HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19th at 12pm Eastern Time.]]>https://www.globenewswire.com/news-release/2019/12/16/1960915/0/en/Salarius-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-Lead-Drug-Candidate-Seclidemstat-in-Relapsed-or-Refractory-Ewing-Sarcoma.html?f=22&fvtc=4&fvtv=55797Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma2019-12-16T13:00:00Z<![CDATA[Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020 Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020]]>